Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 3
2015 3
2016 2
2017 2
2018 2
2020 2
2021 4
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients.
Marchetti C, Palaia I, De Felice F, Musella A, Donfracesco C, Vertechy L, Romito A, Piacenti I, Musio D, Muzii L, Tombolini V, Benedetti Panici P. Marchetti C, et al. Among authors: vertechy l. Cancer Treat Rev. 2016 Jan;42:41-6. doi: 10.1016/j.ctrv.2015.10.011. Epub 2015 Nov 10. Cancer Treat Rev. 2016. PMID: 26559739 Review.
Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions.
Musella A, Vertechy L, Romito A, Marchetti C, Giannini A, Sciuga V, Bracchi C, Tomao F, Di Donato V, De Felice F, Monti M, Muzii L, Benedetti Panici P. Musella A, et al. Among authors: vertechy l. Chemotherapy. 2017;62(2):111-120. doi: 10.1159/000448942. Epub 2016 Oct 29. Chemotherapy. 2017. PMID: 27794568 Review.
Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
Musella A, Bardhi E, Marchetti C, Vertechy L, Santangelo G, Sassu C, Tomao F, Rech F, D'Amelio R, Monti M, Palaia I, Muzii L, Benedetti Panici P. Musella A, et al. Among authors: vertechy l. Cancer Treat Rev. 2018 May;66:7-14. doi: 10.1016/j.ctrv.2018.03.004. Epub 2018 Mar 23. Cancer Treat Rev. 2018. PMID: 29605737 Review.
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review.
Marchetti C, Palaia I, Giorgini M, De Medici C, Iadarola R, Vertechy L, Domenici L, Di Donato V, Tomao F, Muzii L, Benedetti Panici P. Marchetti C, et al. Among authors: vertechy l. Onco Targets Ther. 2014 Jul 10;7:1223-36. doi: 10.2147/OTT.S40947. eCollection 2014. Onco Targets Ther. 2014. PMID: 25031539 Free PMC article. Review.
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study.
Turinetto M, Ricotti A, Marchetti C, Pisano C, Zamagni C, Cassani C, Malaguti P, Baldoni A, Scollo P, Scandurra G, Parisi A, Artioli G, Palaia I, Vertechy L, Bergamini A, Picardo E, Tuninetti V, Scotto G, Scambia G, Pignata S, Valabrega G. Turinetto M, et al. Among authors: vertechy l. Cancers (Basel). 2023 Dec 20;16(1):41. doi: 10.3390/cancers16010041. Cancers (Basel). 2023. PMID: 38201470 Free PMC article.
20 results